The global Amyloidosis Therapeutics Market is poised for substantial growth over the next decade, fueled by rising disease awareness, improved diagnostics, and accelerating research and development investments. Amyloidosis is a rare but serious disorder characterized by the abnormal deposition of amyloid proteins in organs and tissues, leading to progressive organ dysfunction and potentially life-threatening complications. As early diagnosis improves and treatment options expand, the market is entering a transformative phase.

According to the latest industry analysis, the amyloidosis therapeutics market was valued at US$ 2.7 Bn in 2024 and is projected to grow at a CAGR of 8.2% from 2025 to 2035, surpassing US$ 6.3 Bn by the end of 2035. The market’s evolution reflects significant progress in rare disease management and targeted therapeutic innovation.

Explore pivotal insights and conclusions from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86469

Market Overview: The amyloidosis therapeutics industry, though relatively niche compared to other therapeutic segments, is expanding robustly. Growing recognition of rare diseases and advancements in diagnostic tools are enabling earlier and more accurate detection of amyloidosis. This, in turn, is leading to higher treatment uptake.

The market is further supported by an increasing number of patients diagnosed with chronic conditions such as multiple myeloma and chronic inflammatory diseases, which are closely associated with certain forms of amyloidosis. As treatment paradigms shift toward personalized medicine and molecular-level targeting, pharmaceutical companies are intensifying their efforts to develop specialized drug formulations.

Between 2020 and 2024, the market demonstrated steady historical growth, and this trajectory is expected to accelerate during the forecast period from 2025 to 2035.

Key Drivers of Market Growth

1. Increasing Prevalence of Amyloidosis

The rising incidence of amyloidosis is a primary growth driver. Light-chain (AL) amyloidosis represents approximately 70% of systemic amyloidosis cases globally. In Western countries, it remains the most common form of systemic amyloidosis.

In the United States alone, around 4,000 new AL amyloidosis cases are diagnosed annually. The disease is typically identified between ages 50 and 65, though younger patients have also been reported. Moreover, an estimated 29,712 relapsed or refractory cases were recorded in 2023, highlighting the need for advanced treatment options.

Earlier and more precise diagnosis is contributing to a larger treated patient pool, thereby boosting demand for effective and disease-modifying therapies.

2. Rising Investments in Research and Development

Pharmaceutical companies and biotech firms are significantly increasing R&D investments. Focus areas include gene-silencing therapies, molecular-level drug targeting, and personalized treatment strategies.

In November 2024, Intellia Therapeutics announced positive phase 1 clinical data for nexiguran ziclumeran, a potential one-time treatment for ATTR amyloidosis. Such advancements illustrate the growing emphasis on innovative, potentially curative approaches.

Government support, orphan drug designations, and regulatory incentives are further accelerating innovation in this rare disease segment.

Key Players and Industry Leaders

Major players shaping the competitive landscape include:

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• GSK plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Bristol-Myers Squibb Company
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca
• BridgeBio Inc.
• Ionis Pharmaceuticals
• Attralus, Inc.
• Eisai Co., Ltd.

These companies are expanding product pipelines, forming strategic partnerships, and strengthening global distribution networks to maintain competitive advantage.

Recent Developments

• In December 2023, Ionis Pharmaceuticals and AstraZeneca received FDA approval for WAINUA (eplontersen) for hereditary ATTR polyneuropathy.
• In October 2024, Alnylam submitted an sNDA for vutrisiran for ATTR-CM, utilizing a Priority Review Voucher for accelerated review.
• In November 2024, the FDA accepted the supplemental application for vutrisiran for ATTR-CM treatment.

These milestones reflect accelerating regulatory activity and expanding therapeutic options.

Market Segmentation

The amyloidosis therapeutics market is segmented by drug type, indication, distribution channel, and region.

By Drug Type:

• Monoclonal Antibodies
• Proteasome Inhibitors
• Immunomodulators
• Corticosteroids
• Alkylating Agents
• Transthyretin Stabilizers
• Others (RNA Interference Therapeutics, NSAIDs, etc.)

Monoclonal antibodies currently dominate the market due to their ability to selectively target amyloid deposits and modify disease progression.

By Indication:

• AL (Primary) Amyloidosis
• AA (Secondary) Amyloidosis
• Familial ATTR Amyloidosis

AL amyloidosis holds the largest market share owing to its higher prevalence and severe clinical impact.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hospital pharmacies account for a significant share due to the complexity of treatment administration.

Regional Outlook

North America leads the global amyloidosis therapeutics market. Factors contributing to its dominance include advanced healthcare infrastructure, strong R&D capabilities, high disease awareness, and favorable regulatory frameworks.

Recent developments further highlight the region’s leadership. In November 2024, Attralus, Inc. received orphan drug designation from the U.S. FDA for AT-02 for treating transthyretin-associated amyloidosis (ATTR). Additionally, Alnylam Pharmaceuticals announced regulatory submissions for vutrisiran targeting ATTR amyloidosis with cardiomyopathy (ATTR-CM).

Europe also demonstrates steady growth, supported by strong rare disease policies and expanding clinical research networks. Asia Pacific is emerging as a promising market due to improving healthcare access and rising investments in biotechnology.

Buy this Premium Research Report for key findings and thorough analysis – https://www.transparencymarketresearch.com/checkout.php?rep_id=86469&ltype=S

New Opportunities and Challenges

Opportunities:

• Expansion of RNA interference therapies
• Growth in personalized medicine
• Increasing global rare disease awareness
• Emerging markets with improving healthcare infrastructure

Challenges:

• High treatment costs
• Limited patient pool
• Complex diagnostic pathways
• Regulatory hurdles in emerging markets

Balancing affordability with innovation remains a central challenge for industry stakeholders.

Market Trends & Innovations

• Rise of gene-editing and RNA-based therapeutics
• Increased orphan drug designations
• Growth in combination therapy approaches
• Adoption of precision diagnostics
• Development of self-administered drug formulations

Innovations in molecular targeting are redefining treatment standards and improving patient outcomes.

Key Trends for the Future

• Shift toward curative, one-time therapies
• Broader use of biomarker-driven treatment selection
• Increased global clinical trial activity
• Strengthening collaboration between biotech and pharma firms
• Enhanced patient access programs

Important FAQs with Answers

How big was the global amyloidosis therapeutics market in 2024?
The market was valued at US$ 2.7 Bn in 2024.

How large will the market be by 2035?
It is projected to surpass US$ 6.3 Bn by the end of 2035.

What is the expected CAGR from 2025 to 2035?
The market is expected to grow at a CAGR of 8.2%.

What factors are driving market growth?
Key drivers include increasing disease prevalence, rising R&D investments, improved diagnostics, and innovative drug development.

Which region leads the market?
North America currently holds the largest market share.

Who are the major players?
Prominent companies include Pfizer, Johnson & Johnson, GSK, Takeda, Amgen, Bristol-Myers Squibb, Alnylam, AstraZeneca, BridgeBio, Ionis, Attralus, and Eisai.

Explore Latest Research Reports by Transparency Market Research:

Lactated Ringers Injection Market: https://www.transparencymarketresearch.com/lactated-ringers-injection-market.html

Neonatal Toxicology Market: https://www.transparencymarketresearch.com/neonatal-toxicology-market.html

Wound Cleanser Market: https://www.transparencymarketresearch.com/wound-cleanser-market.html

Cluster Headache Market: https://www.transparencymarketresearch.com/cluster-headache-market.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453